- Home
- »
- Healthcare IT
- »
-
AI in Medical Writing Market Size & Share Report, 2026-2033GVR Report cover
AI in Medical Writing Market (2026 - 2033)
Size, Share & Trends Analysis Report By Type (Clinical Writing, Type Writing, Scientific Writing), By End-use (Medical Devices, Pharmaceutical, Biotechnology), By Region, And Segment Forecasts
Market Size, 2025
$1.0BMarket Estimate, 2026
$1.2BMarket Forecast, 2033
$3.5BCAGR, 2026–2033
16.4%AI In Medical Writing Market Summary
The global AI in medical writing market size was valued at USD 1.0 billion in 2025 and is projected to grow from USD 1.2 billion in 2026 to USD 3.5 billion by 2033, at a CAGR of 16.4% from 2026 to 2033. The market in North America dominated with a revenue share of 36.5% in 2025. The adoption of AI in medical writing is significantly accelerating the production of regulatory documents, clinical study reports, and scientific publications.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,
Download Free Sample Report Key Market Trends & Insights
- By type: Type writing segment held the largest market share of 33.0% in 2025.
- By end use: Pharmaceutical segment held the largest market share of 33.4% in 2025.
Regional Highlights
- Largest regional market: North America (36.5% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025
Market Size & Forecasts
- Market size in 2025: USD 1.0 Billion
- Estimated market size in 2026: USD 1.2 Billion
- Projected market size by 2033: USD 3.5 Billion
- CAGR (2026-2033): 16.4%
Three ways to get this report
Buy it, customize it, or ask a question.Ask an Analyst
Analyst response in 1 business day
- AccessReport author, directly
- Reply timeWithin 1 working day
- No sales callDirect answer only
- FormatEmail reply
- CostFree, no cost
Get the Full Report
What the study covers
- FormatsPDF · Excel · Dashboard
- Timeline2026–2033 annual, 2025 base
- Coverage20+ countries, 5 regions
- Companies10+ key players profiled
Customize the Report
20% free customization
- IncludeCountries, segments, points
- TailorTo your product definition
- ExtendDeeper competitor detail
- OrA fully bespoke study
- Turnaround5–10 working days
AI-driven tools streamline repetitive tasks, such as data extraction, summarization, and template generation, reducing human error and enabling faster project turnarounds. For instance, in June 2024, TrialAssure, a company focused on clinical trial disclosure, data sharing, and transparency, unveiled TrialAssure LINK AI 2.0. The updated version is tailored to support pharmaceutical and biotechnology companies, clinical research organizations, and service providers in efficiently drafting common regulatory and medical writing documents using advanced AI technology.
To learn more about this report, Download Free Sample Report Artificial intelligence (AI) ensures compliance with stringent regulatory requirements by offering accurate, consistent, and error-free documentation. Natural language processing (NLP) algorithms are equipped to detect inconsistencies and align content with guidelines set by agencies like the FDA and EMA. This capability is critical in the medical writing industry, where non-compliance can lead to delays or rejections. The assurance of producing high-quality, regulation-compliant content has driven organizations to adopt AI technologies to meet evolving standards.
Integrating AI with data analytics has allowed real-time insights, enabling dynamic content creation tailored to specific clinical findings or market trends. These tools can interpret large volumes of clinical trial data and translate them into structured and coherent documents. AI-driven platforms enhance the ability of medical writers to produce highly targeted and scientifically robust content, which is essential for gaining a competitive edge. This integration between AI and analytics fosters market growth across the pharmaceutical and biotech sectors.
AI enables the creation of personalized medical content, addressing the specific needs of healthcare professionals, patients, and regulatory bodies. Customization is increasingly valued in the industry as it enhances the communication of complex medical information. For instance, AI algorithms can generate different versions of a single document to cater to diverse audiences. This flexibility supports precision in communication, making AI an indispensable tool for companies looking to engage stakeholders effectively.
The adoption of AI in medical writing is rapidly growing in emerging markets due to increased investments in pharmaceutical and clinical research. Countries in Asia-Pacific, the Middle East, and Latin America are leveraging AI to overcome challenges such as skill shortages and high documentation demand. Governments and private organizations are funding AI-driven solutions to boost their healthcare and research capabilities. The expansion of AI applications in these regions highlights its pivotal role in advancing global medical writing practices, further propelling the market’s growth.
Market Dynamics
The increasing adoption of generative AI across pharmaceutical, biotechnology, and contract research organizations (CROs) is a key factor driving growth in the AI medical writing market. As companies manage growing volumes of clinical trial data, regulatory submissions, study reports, and scientific publications, AI-powered solutions are increasingly being deployed to automate document drafting, content summarization, literature reviews, and data extraction. These capabilities reduce manual effort, improve consistency, and shorten document preparation timelines, enabling organizations to accelerate drug development and regulatory approval processes.
Furthermore, the industry is transitioning from pilot programs toward broader AI integration within clinical development and regulatory workflows. According to a global survey conducted by the Tufts Center for the Study of Drug Development, nearly 63% of organizations plan to pilot, partially implement, or fully implement AI and machine learning technologies in clinical development and regulatory submissions by 2025. Increased emphasis on operational efficiency is also encouraging investments in generative AI, with stakeholders reporting improvements in document-authoring speed, scalability, and workflow productivity.
Production-Scale Instances
• Parexel's Clinical Report Automation: Global contract research organization (CRO) Parexel deployed a generative AI application that achieved an approximately 40% reduction in the time required to draft patient narratives and core clinical study reports (CSRs), substantially reducing manual data extraction and copy-paste activities.
• Indegene's Regulatory Writing Platform: Indegene introduced a proprietary generative AI-enabled regulatory writing platform equipped with real-time compliance capabilities that cross-reference current FDA and EMA submission requirements, enabling the identification of inconsistencies, missing information, and potential gaps prior to human review.
• Celegence's CMC Module 3 Automation: Celegence collaborated with Kenvue to implement its CAPTIS generative AI platform for automating the preparation of CMC Module 3 regulatory documents intended for submissions to agencies such as the FDA and MHRA, demonstrating the application of generative AI in regulatory medical writing workflows.
• Saama Technologies' Clinical Query Automation: Saama Technologies implemented an AI-driven workflow automation solution to identify and resolve anomalies in trial master files, reducing the average timeline for detecting and generating data queries from approximately 25 days to 1.7 days, thereby enhancing operational efficiency in clinical development processes.
These production-scale deployments demonstrate the industry's transition from pilot initiatives to enterprise-wide adoption of generative AI, enabling medical writers to shift from labor-intensive content generation toward higher-value scientific review, quality assurance, and human-in-the-loop verification activities while supporting accelerated drug development timelines.
A major challenge for AI in medical writing is the stringent regulatory environment governing clinical, regulatory, and pharmaceutical documentation. Outputs for clinical trial reports, regulatory submissions, and safety documentation must comply with global standards, including Good Clinical Practice (GCP) and guidelines from authorities such as the FDA and EMA. These standards require complete accuracy and scientific rigor, as well as auditability, making it difficult to deploy AI-generated content without robust governance and control.
AI models in medical writing also face challenges with reliability and consistency. Problems such as hallucinated information, lack of transparency, and difficulty tracing the origins of outputs raise compliance concerns. Thus, multiple layers of human review, medical validation, and quality assurance are required before submitting AI-assisted content for regulatory purposes.
Moreover, integrating AI into regulated workflows requires algorithm validation and periodic re-validation after updates. This creates significant operational burdens for pharmaceutical companies and clinical research organizations, as they must ensure AI tools meet both internal quality standards and external regulatory requirements. Consequently, rigorous validation frameworks increase time-to-market and slow the scaling of AI adoption in medical writing.
AI technologies are increasingly being utilized to support a wide range of activities. By automating repetitive and time-intensive tasks, AI enables medical writers to focus on higher-value activities such as scientific analysis, content strategy, and quality review, thereby improving overall productivity and operational efficiency. Furthermore, advancements in generative AI and natural language processing are creating opportunities to develop comprehensive end-to-end medical writing solutions. As pharmaceutical and biotechnology organizations seek to accelerate drug development timelines and manage growing volumes of clinical and regulatory data, the demand for AI-powered platforms capable of streamlining documentation workflows is expected to increase. The continued evolution of domain-specific AI models, coupled with improved integration into regulatory and clinical systems, is likely to expand the role of AI across the entire medical writing ecosystem.
Key Opportunities for AI in Medical Writing
Opportunity Area
Application in AI Medical Writing
Key Benefit
Regulatory Document Generation
Automated drafting of Clinical Study Reports (CSRs), Common Technical Documents (CTDs), Investigator Brochures (IBs), patient narratives, and submission dossiers
Reduces authoring time, improves consistency, and accelerates regulatory submissions
Literature Review and Evidence Synthesis
AI-assisted screening, summarization, and extraction of information from scientific publications and clinical studies
Shortens literature review timelines and supports evidence-based decision-making
Content Summarization and Data Extraction
Extraction and summarization of key findings from clinical trial databases, study reports, and scientific publications
Minimizes manual effort and enhances productivity
Medical Publication Writing
Generation of first drafts for manuscripts, abstracts, conference posters, and scientific presentations
Increases writing efficiency while allowing experts to focus on scientific review
Compliance and Quality Review
Automated review of documents against FDA, EMA, and ICH guidelines to identify inconsistencies, omissions, and formatting issues
Enhances submission quality and reduces rework
Patient-Centric Content Development
Preparation of plain-language summaries, informed consent forms, and patient education materials
Improves readability, accessibility, and patient engagement
Market Concentration & Characteristics
The degree of innovation in the AI in medical writing industry is exceptionally high, driven by advancements in natural language processing (NLP) and machine learning. These technologies enable real-time drafting, editing, and summarization of complex medical documents. Custom AI solutions are increasingly tailored for regulatory compliance, clinical trial documentation, and scientific writing, enhancing efficiency, accuracy, and scalability across the pharmaceutical and biotech sectors.
The AI in medical writing industry is witnessing a moderate yet steadily increasing level of mergers and acquisitions (M&A) activity. Companies are pursuing strategic acquisitions to enhance AI capabilities, integrate innovative technologies, and expand their service offerings. For instance, in October 2023, Springer Nature strengthened its AI capabilities with the acquisition of Slimmer AI's Science division. As technology continues to enhance the publishing of trusted scientific content, the global academic publisher announced a definitive agreement to integrate the Netherlands-based Slimmer AI’s Science division into its operations. These M&A efforts aim to drive efficiency, streamline regulatory processes, and strengthen market positions in the rapidly evolving medical writing domain.
To learn more about this report, Download Free Sample Report Regulations significantly impact AI in medical writing industry by ensuring compliance, safety, and ethical use of AI technologies. Strict regulatory frameworks necessitate transparency, data privacy, and adherence to industry standards, which can slow innovation but enhance trust and reliability. Regulatory approvals for AI tools, particularly in pharmaceutical and healthcare applications, shape market growth, driving developers to prioritize quality and accountability while fostering confidence among stakeholders in adopting these advanced solutions.
The growing need for efficient and accurate documentation in the pharmaceutical and healthcare industries drives product expansion in the AI in medical writing industry. Companies are introducing advanced AI-driven tools that streamline regulatory submissions, clinical trial reporting, and scientific content creation. Features like multilingual support, generative AI integration, and real-time collaboration enhance productivity.
Geographical expansion in the AI in medical writing industry is fueled by increasing global demand for streamlined medical documentation and regulatory compliance. Companies are targeting emerging markets in Asia-Pacific, Latin America, and the Middle East, where pharmaceutical and clinical research activities are rising. By establishing regional offices, forming strategic partnerships, and offering localized AI solutions, businesses are addressing diverse regulatory requirements and boosting adoption across global healthcare and life sciences sectors.
Analyst Perspective
Rising demand for automation, regulatory efficiency, and faster clinical documentation in the pharmaceutical, biotechnology, and healthcare sectors is driving growth in the AI medical writing market. Organizations are adopting AI-powered solutions to streamline clinical trial documentation and scientific writing. Established companies leverage regulatory expertise and global networks to maintain their market position, while new entrants introduce advanced generative AI tools to improve speed and efficiency. However, challenges such as compliance complexity, limited adoption of advanced AI in legacy systems, and regulatory validation requirements persist. Despite these constraints, the market is steadily evolving toward more automated and intelligent medical writing ecosystems.
Case Study Moderna develops 750 GPTs, significantly accelerating AI adoption
OpenAI recently published a case study highlighting their collaboration with Moderna, showcasing how the pharmaceutical giant is leveraging ChatGPT Enterprise to transform operations. By integrating AI across departments, Moderna is reimagining processes in legal, research, manufacturing, and commercial functions, aiming for an organization-wide redesign powered by AI.
Moderna’s leadership is committed to this transformation, with their CEO stating:
"We believe very profoundly at Moderna that ChatGPT and what OpenAI is doing is going to change the world. We’re looking at every business process—and thinking about how to redesign them with AI."
To achieve this vision, Moderna rolled out ChatGPT Enterprise to thousands of employees, setting an ambitious goal of 100% adoption and proficiency in generative AI within six months. Results indicate significant progress:
-
employees across the organization created 750 custom GPTs.
-
40% of weekly active users developed their GPTs tailored to their workflows.
-
On average, each user engaged in 120 weekly conversations with ChatGPT.
This integration highlights the potential of AI in medical writing, a critical function in the pharmaceutical industry. AI-enabled tools can assist in drafting clinical trial documentation, summarizing research data, automating compliance reports, and streamlining communication with regulatory bodies. The ability to create custom GPTs allows employees to design solutions for specific medical writing challenges, such as adapting complex scientific content into reader-friendly formats or ensuring consistency in style and tone across documents.
Type Insights
Based on type, the type writing segment led the market with the largest revenue share of 33.0% in 2025. This segment plays a crucial role throughout the entire product development process, particularly in scientific documentation. Typewriting is essential for the proper organization and presentation of data from clinical trials, which is required for regulatory submissions and product authorization. Upon receiving approval for a drug or product, post-approval regulatory certification becomes mandatory, necessitating additional paperwork and documentation. Due to the stringent regulations and extensive documentation requirements, there has been a surge in demand for efficient and accurate medical writing, further driving the growth of this segment.
The clinical writing segment, on the other hand, is expected to experience the fastest CAGR of 17.2% during the forecast period. Clinical writing is regularly used by medical professionals for various purposes, including patient documentation, clinical trial reporting, and regulatory submissions. Clinical writers need to have a comprehensive understanding of the clinical field, medical terminology, and the language used in medical documentation. In addition, they must be able to effectively communicate with both clinical professionals and regulatory bodies, which requires expertise in understanding the target audience and purpose of the writing.
End Use Insights
Based on end use, the pharmaceutical segment led the market with the largest revenue share of 33.4% in 2025, Pharmaceutical companies make substantial investments in research and development (R&D) to create innovative drugs and treatments. These efforts generate extensive data from clinical trials, preclinical studies, and scientific literature, providing a rich source for training AI models used in medical writing tasks.
To learn more about this report, Download Free Sample Report The adoption of AI-enabled solutions has significantly streamlined the medical writing process, with many companies reporting notable reductions in the time required for these tasks. Specifically, AI-powered tools can automate substantial portions of the Clinical Study Report (CSR) writing process, enhancing efficiency and accuracy. The time savings achieved through CSR automation solutions vary by provider. For instance, ZYLiQ.ai, a player in the industry, claims its solutions can reduce the time medical writers spend on tasks by 60-70%. This growing reliance on AI-driven technologies underscores the pharmaceutical sector’s pivotal role in advancing the adoption of AI in medical writing.
The medical devices segment is projected to experience the fastest CAGR of 17.5% during the forecast period. Medical writing is a critical component of the medical device development process, involving preparing documents such as clinical trial protocols, investigator brochures, patient information leaflets, and regulatory submissions. These documents provide essential insights into device safety, efficacy, and usage. Furthermore, medical writing documents the scientific rationale, regulatory compliance, and clinical data supporting device development. This ensures a clear narrative, aiding regulatory approvals and establishing credibility in the device's design, development, and effectiveness.
Regional Insights
North America dominated the AI in medical writing market with the largest revenue share of 36.5% in 2025. North America AI in medical writing market is experiencing robust growth, driven by advancements in AI technology and its application in medical writing processes. According to a Science Direct report published in September 2024, AI can streamline manuscript preparation by aligning content with journal guidelines and expediting the peer-review process. This time-saving capability enhances efficiency, enabling researchers and writers to focus on critical tasks, fueling market expansion across the region.
To learn more about this report, Download Free Sample Report U.S. AI In Medical Writing Market Trends
The medical writing market in the U.S. held the largest share in the North America region in 2025. The U.S. AI in medical writing market is growing rapidly, driven by technological advancements and innovative solutions. Cutting-edge AI tools streamline regulatory writing, data analysis, and content generation, improving accuracy and efficiency. For instance, in August 2023, Celegence introduced CAPTIS Copilot, an AI-driven compliance solution for medical device and diagnostic manufacturers. The platform is designed to streamline regulatory processes, including medical writing tasks such as crafting clinical evaluation reports, regulatory submissions, and post-market surveillance documentation. Leveraging advanced AI capabilities, CAPTIS Copilot enhances document accuracy, compliance, and efficiency, ensuring manufacturers meet stringent global regulatory standards.
Europe AI In Medical Writing Market Trends
AI in medical writing market in Europe is expanding due to several key factors, including robust investment in AI research, strong pharmaceutical and biotech industries, and increasing adoption of digital transformation in healthcare. Advanced AI solutions enhance compliance with stringent European regulatory frameworks, streamline document creation, and improve efficiency. Collaborative efforts among industry players further drive innovation, solidifying Europe as a leader in integrating AI into medical writing processes.
The UK AI in medical writing market is growing due to the technology's ability to save time and simplify complex tasks. AI-powered tools streamline the creation of regulatory and scientific documents, reducing manual effort. Their user-friendly interfaces make them accessible to professionals across sectors, enhancing productivity and supporting the UK's thriving pharmaceutical and biotechnology industries.
AI in medical writing market in Germany is witnessing growth driven by innovation and the rising demand for scientific writing solutions. The introduction of AI tools like Springer Nature's Curie in October 2023 highlights this trend. Curie assists researchers in crafting scientific documents efficiently, addressing the increasing need for precision and speed in Germany's dynamic pharmaceutical and research sectors.
Asia Pacific AI In Medical Writing Market Trends
Asia Pacific is expected to be the fastest growing region over the forecast period and is growing rapidly, fueled by increasing demand for efficient and accurate scientific writing solutions. Rising pharmaceutical research activities and a growing need to streamline regulatory documentation processes are driving adoption. AI tools offer time-saving benefits and enhanced accuracy, making them indispensable in meeting the region's expanding medical and scientific communication requirements.
AI in medical writing market in Japan is experiencing significant growth, driven by advancements in AI technology and the nation's focus on precision and innovation. AI-powered tools streamline scientific documentation, improve accuracy, and reduce time spent on regulatory submissions, making them vital for Japan's expanding pharmaceutical and biotechnology industries.
AI in medical writing market in China is growing rapidly, driven by the increased adoption of AI tools to enhance productivity and streamline scientific writing processes. For instance, a 2023 Springer Nature report highlighted that 90% of Chinese researchers who used AI-assisted tools during trials advanced their manuscripts to peer review, resulting in a 14% rise in published articles.
Key AI In Medical Writing Company Insights
Some major players catering to the AI in medical writing industry are Parexel International (MA) Corporation; Trilogy Writing & Consulting GmbH; Freyr; Cactus Communications; GENINVO; IQVIA Inc.; ICON plc; Syneos Health; among others. There are various small and large manufacturers offering products, resulting in intense competition among the manufacturers. The industry players are increasing their focus on strategic partnerships such as mergers and acquisitions, new product launches & partnerships & collaborations to get maximum revenue share in this sector.
Key AI In Medical Writing Companies
The following key companies have been profiled for this study on the AI in medical writing market.
-
Parexel International (MA) Corporation
-
Certara, Inc.
-
Trilogy Writing & Consulting GmbH
-
Freyr
-
Cactus Communications
-
GENINVO
-
IQVIA Inc.
-
ICON plc
-
Syneos Health
-
IBM
-
Teladoc Health, Inc.
-
SmarterDx
-
Abridge Al, Inc.
-
Suki AI, Inc.
-
Movano
-
Heidi
-
Corti
-
Tortus AI.
-
Nabla Technologies
Competitive Benchmarking
Operating Strategies
Competitive Edge
Weaknesses
Established Players (e.g., IQVIA, ICON plc)
- Focus on integrating AI capabilities into clinical research, regulatory writing, and drug development services through established CRO and pharma partnerships.
- Expand service offerings by embedding AI tools into existing medical writing, clinical trial management, and compliance workflows.
- Strong global client base with deep regulatory and clinical research expertise.
- Established infrastructure and trusted reputation in pharmaceutical and life sciences ecosystems.
- Slower adoption of advanced generative AI and automation technologies.
- High operational complexity and dependence on traditional service-based delivery models.
Emerging Players (e.g., Abridge AI, Suki AI)
- Develop AI-first platforms focused on generative AI, ambient clinical documentation, and automated medical writing tools.
- Target direct adoption by healthcare providers through lightweight, cloud-based, and workflow-integrated solutions.
- Rapid innovation cycles with strong focus on cutting-edge AI and machine learning capabilities.
- High flexibility and user-centric product design enabling quick deployment and adoption.
- Limited experience in regulatory-grade medical writing and compliance-heavy documentation.
- Lower enterprise penetration and relatively limited global market reach.
Recent Developments
-
In June 2024, Certara, Inc. introduced its next-generation CoAuthor regulatory writing software, an innovative platform tailored for medical writers. CoAuthor integrates generative AI, pre-designed templates, Microsoft Word compatibility, and structured content authoring tools. This advanced solution streamlines the creation of regulatory documents, ensuring efficiency while upholding a "human-in-the-loop" approach to maintain quality and oversight in AI-assisted writing.
-
In July 2024, Cognizant announced a partnership with Yseop, a leading AI software company, to accelerate and scale scientific content delivery in the biopharma industry using generative AI. By leveraging Yseop Copilot to revolutionize medical writing in life sciences, the collaboration aims to boost productivity in drug development and expedite the launch of life-saving treatments. Cognizant is committed to driving Yseop's value and adoption across the life sciences sector, further advancing the digital transformation powered by AI.
-
In October 2023, Springer Nature introduced a new AI-powered in-house writing assistant designed to assist researchers, especially those whose first language is not English, in enhancing their scientific writing. Studies indicate that non-native English-speaking scientists require 51% more time to write a research paper, creating disparities in global research. This initiative aims to bridge the gap, fostering equal opportunities for high-quality research submissions worldwide.
AI In Medical Writing Market Report Scope
Report Attribute
Details
Market size in 2025
USD 1.0 billion
Estimated market size in 2026
USD 1.2 billion
Projected market size by 2033
USD 3.5 billion
Growth rate
CAGR of 16.4% from 2026 to 2033
Historical data
2021 - 2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million/billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Type, end use, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; UK; Germany; Spain; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
Parexel International (MA) Corporation; Trilogy Writing & Consulting GmbH; Freyr; Cactus Communications; GENINVO; IQVIA Inc.; ICON plc; Syneos Health; IBM; Teladoc Health, Inc.; SmarterDx; Abridge AI, Inc.; Suki AI, Inc.; Movano; Heidi; Corti; Tortus AI; Nabla Technologies, Certara, Inc.
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchasse. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global AI In Medical Writing Market Report Segmentation
This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global AI in medical writing market report based on type, end use, and region:
To learn more about this report, Download Free Sample Report -
Type Outlook (Revenue, USD Million, 2021 - 2033)
-
Clinical Writing
-
Type Writing
-
Scientific Writing
-
Others
-
-
End Use Outlook (Revenue, USD Million, 2021 - 2033)
-
Medical Devices
-
Pharmaceutical
-
Biotechnology
-
Others
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
South Korea
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Research Methodology
The AI in medical writing market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each AI in medical writing segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Type
Revenue capture definition
Clinical Writing
This segment includes AI-driven solutions used to generate and manage clinical documents such as clinical study reports, trial protocols, and regulatory submissions. Revenue is generated from tools that improve accuracy and efficiency in clinical documentation workflows.
Type Writing
This segment captures revenue from AI platforms that assist in producing structured technical documents such as regulatory guidelines, product manuals, and compliance-related content. It focuses on improving clarity and documentation speed.
Scientific Writing
Revenue in this segment is generated from AI tools used to support research papers, journals, manuscripts, and scientific publications. These solutions help researchers and medical writers improve content quality, language accuracy, and publication readiness.
Others
This segment includes AI-enabled solutions for additional medical writing applications such as educational content, marketing material, and healthcare communication documents. It supports broader documentation needs across the healthcare ecosystem.
Segment – End Use
Revenue capture definition
Medical Devices
This segment includes revenue generated from AI medical writing tools used by medical device companies for regulatory documentation, product labeling, clinical evaluations, and technical file preparation.
Pharmaceutical
Revenue is driven by pharmaceutical companies using AI for clinical trial documentation, drug regulatory submissions, safety reports, and research publications, improving compliance and documentation efficiency.
Biotechnology
This segment captures revenue from biotech firms utilizing AI tools for research documentation, clinical study reports, and scientific publications, supporting innovation and faster time-to-market.
Others
This includes academic institutions, research organizations, and healthcare service providers using AI medical writing tools for training materials, publications, and general healthcare communication.
Estimation Model
Model Details:
The AI in medical writing market represents a high-growth, transformative segment within healthcare AI applications, driven by automation of clinical documentation, regulatory writing, medical summarization, and content generation. The market includes global key players such as Parexel International Corporation, Certara Inc., IQVIA Inc., Syneos Health, ICON plc, Cactus Communications, IBM, Freyr, Trilogy Writing & Consulting GmbH, GENINVO, Teladoc Health, SmarterDx, Abridge AI Inc., and Suki.
To ensure a comprehensive and triangulated approach, the GVR research team applied a structured methodology incorporating multiple analytical models and data validation layers across stakeholders, geographies, and end users.
Our methodology included:
Model 1: Digital Content & Workflow Flow Analysis: For public players, annual reports, AI/clinical documentation disclosures, and digital health segment revenues were analyzed. For private players, premium intelligence sources such as S&P Global, Crunchbase, ZoomInfo, and RocketReach were used to estimate AI adoption in medical writing workflows. The analysis tracked AI penetration across clinical documentation, regulatory submissions, pharmacovigilance reports, and medical communications.
Model 2: Parent Market Analysis
Model 3: Country-level Multivariate Analysis Assumptions
Model 4: Segment-level Multivariate Analysis Assumptions
Model 5: AI in Medical Writing Market CAGR Calculations
Model 1: Commodity Flow Analysis
To learn more about this report, Download Free Sample Report Digital flow analysis was used to map how AI-generated content moves through the medical writing value chain from AI platform providers and NLP model developers to CROs, pharmaceutical companies, and regulatory agencies. The analysis captured efficiency gains in document generation, review cycles, compliance validation, and submission readiness, highlighting key points of AI-driven value creation and adoption.
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
AI-Enabled Medical Writing Demand & Service Transformation Assessment
A comprehensive market analysis was delivered covering the evolving demand for AI-enabled medical writing services across pharmaceutical companies, CROs, biotech firms, and digital health organizations. The assessment integrated capabilities and positioning of key players. The study evaluated shifting outsourcing preferences toward AI-assisted regulatory writing, clinical documentation automation, and scientific content generation.
This delivered analysis enables stakeholders to identify high-growth service segments such as AI-driven clinical documentation, pharmacovigilance writing, and regulatory submission support. It also supports forecasting demand shifts driven by increasing clinical trial complexity, rising regulatory workloads, and adoption of generative AI in life sciences communication.
Regulatory, Clinical & Scientific Writing Intelligence Evaluation
A structured evaluation was conducted on AI applications across regulatory documentation, clinical study reports, medical publications, and scientific communication workflows. The analysis also included AI-assisted clinical documentation innovators for adjacent healthcare documentation intelligence capabilities.
This delivered framework provides actionable insights into how AI is improving regulatory compliance accuracy, accelerating manuscript development, and enhancing clinical narrative generation.
Life Sciences AI Ecosystem, Workflow Integration & Competitive Positioning Assessment
A detailed ecosystem mapping was delivered covering AI integration across pharmaceutical IT systems, EHR platforms, CTMS environments, and healthcare communication tools. Digital health AI innovators were analyzed for their contribution to clinical data capture and structured documentation workflows.
This delivered analysis supports strategic decision-making around technology adoption, partnership models, and competitive differentiation. It highlights how AI-driven interoperability is improving content generation and reducing manual intervention.
Frequently Asked Questions About This Report
Asia Pacific is the fastest-growing region over the forecast period.
The type writing segment led with a 33.0% revenue share in 2025, while the clinical writing segment is the fastest-growing type.
The pharmaceutical segment led with a 33.4% revenue share in 2025, while the medical devices is the fastest-growing segment.
Some of the key players operating in the AI in medical writing market include Parexel International (MA) Corporation; Trilogy Writing & Consulting GmbH; Freyr; Cactus Communications; GENINVO; IQVIA Inc.; ICON plc; Syneos Health; IBM; Teladoc Health, Inc.; SmarterDx; Abridge AI, Inc.; Suki AI, Inc.; Movano; Heidi; Corti; Tortus AI; Nabla Technologies, Certara, Inc.
The AI in medical writing market is driven by increasing demand for precision in regulatory documentation, cost-efficient content generation, advancements in natural language processing, and growing adoption of AI in healthcare communication.
The global AI in medical writing market size was valued at USD 1.0 billion in 2025 and is estimated at USD 1.2 billion for 2026.
The global AI in medical writing market is expected to grow at a CAGR of 16.4% from 2026 to 2033, reaching USD 3.5 billion by 2033.
North America dominated with a 36.5% revenue share in 2025.
About the Author(s)
Healthcare IT Research Team
Healthcare · Healthcare ITThis report was authored by the healthcare it research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the healthcare it segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
